Report Detail
Global Duchenne Muscular Dystrophy Drugs Market Professional Survey Report 2019
- RnM3721285 |
- 03 September, 2019 |
- Global |
- 122 Pages |
- QYResearch |
- Pharma & Healthcare
Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essential for maintaining healthy muscle function) in individuals. The lack of dystrophin weakens muscle function, causes loss of ambulation, harms the respiratory and cardiac function, and ultimately leads to death.
The main symptoms of this condition appears in childhood and includes delay of motor functions; progressive muscle weakness; muscle contractures in legs; and muscle weakness in arms, neck, and more severely in the lower half of the body. The bones also develop peculiarly, causing skeletal deformities in the patient. Occurrences of pseudo-hypertrophy, cardiomyopathy, and breathing complications are some of the other symptoms of this condition.
The global Duchenne Muscular Dystrophy Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Duchenne Muscular Dystrophy Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Duchenne Muscular Dystrophy Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Duchenne Muscular Dystrophy Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Duchenne Muscular Dystrophy Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Akashi Therapeutics Inc
Antisense Therapeutics Ltd
Beech Tree Labs Inc
Biogen Inc
Bioleaders Corp
BioMarin Pharmaceutical Inc
Biophytis SAS
Capricor Therapeutics Inc
Catabasis Pharmaceuticals Inc
CRISPR Therapeutics
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
FibroGen Inc
Fulcrum Therapeutics Inc
Galapagos NV
Genethon SA
GTx Inc
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics Inc
SOM Biotech SL
Strykagen Corp
Summit Therapeutics Plc
Taiho Pharmaceutical Co Ltd
Teijin Pharma Ltd
WAVE Life Sciences Ltd
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Development & Drug Target
Mechanism of Action (MoA)
Route of Administration (RoA)
Molecule Type
Segment by Application
Hospitals and Clinics
Medical Laboratories
Others
Table of Contents
Executive Summary
1 Industry Overview of Duchenne Muscular Dystrophy Drugs
- 1.1 Definition of Duchenne Muscular Dystrophy Drugs
- 1.2 Duchenne Muscular Dystrophy Drugs Segment by Type
- 1.2.1 Global Duchenne Muscular Dystrophy Drugs Production Growth Rate Comparison by Types (2014-2025)
- 1.2.2 Development & Drug Target
- 1.2.3 Mechanism of Action (MoA)
- 1.2.4 Route of Administration (RoA)
- 1.2.5 Molecule Type
- 1.3 Duchenne Muscular Dystrophy Drugs Segment by Applications
- 1.3.1 Global Duchenne Muscular Dystrophy Drugs Consumption Comparison by Applications (2014-2025)
- 1.3.2 Hospitals and Clinics
- 1.3.3 Medical Laboratories
- 1.3.4 Others
- 1.4 Global Duchenne Muscular Dystrophy Drugs Overall Market
- 1.4.1 Global Duchenne Muscular Dystrophy Drugs Revenue (2014-2025)
- 1.4.2 Global Duchenne Muscular Dystrophy Drugs Production (2014-2025)
- 1.4.3 North America Duchenne Muscular Dystrophy Drugs Status and Prospect (2014-2025)
- 1.4.4 Europe Duchenne Muscular Dystrophy Drugs Status and Prospect (2014-2025)
- 1.4.5 China Duchenne Muscular Dystrophy Drugs Status and Prospect (2014-2025)
- 1.4.6 Japan Duchenne Muscular Dystrophy Drugs Status and Prospect (2014-2025)
- 1.4.7 Southeast Asia Duchenne Muscular Dystrophy Drugs Status and Prospect (2014-2025)
- 1.4.8 India Duchenne Muscular Dystrophy Drugs Status and Prospect (2014-2025)
2 Manufacturing Cost Structure Analysis
- 2.1 Raw Material and Suppliers
- 2.2 Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy Drugs
- 2.3 Manufacturing Process Analysis of Duchenne Muscular Dystrophy Drugs
- 2.4 Industry Chain Structure of Duchenne Muscular Dystrophy Drugs
3 Development and Manufacturing Plants Analysis of Duchenne Muscular Dystrophy Drugs
- 3.1 Capacity and Commercial Production Date
- 3.2 Global Duchenne Muscular Dystrophy Drugs Manufacturing Plants Distribution
- 3.3 Major Manufacturers Technology Source and Market Position of Duchenne Muscular Dystrophy Drugs
- 3.4 Recent Development and Expansion Plans
4 Key Figures of Major Manufacturers
- 4.1 Duchenne Muscular Dystrophy Drugs Production and Capacity Analysis
- 4.2 Duchenne Muscular Dystrophy Drugs Revenue Analysis
- 4.3 Duchenne Muscular Dystrophy Drugs Price Analysis
- 4.4 Market Concentration Degree
5 Duchenne Muscular Dystrophy Drugs Regional Market Analysis
- 5.1 Duchenne Muscular Dystrophy Drugs Production by Regions
- 5.1.1 Global Duchenne Muscular Dystrophy Drugs Production by Regions
- 5.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Regions
- 5.2 Duchenne Muscular Dystrophy Drugs Consumption by Regions
- 5.3 North America Duchenne Muscular Dystrophy Drugs Market Analysis
- 5.3.1 North America Duchenne Muscular Dystrophy Drugs Production
- 5.3.2 North America Duchenne Muscular Dystrophy Drugs Revenue
- 5.3.3 Key Manufacturers in North America
- 5.3.4 North America Duchenne Muscular Dystrophy Drugs Import and Export
- 5.4 Europe Duchenne Muscular Dystrophy Drugs Market Analysis
- 5.4.1 Europe Duchenne Muscular Dystrophy Drugs Production
- 5.4.2 Europe Duchenne Muscular Dystrophy Drugs Revenue
- 5.4.3 Key Manufacturers in Europe
- 5.4.4 Europe Duchenne Muscular Dystrophy Drugs Import and Export
- 5.5 China Duchenne Muscular Dystrophy Drugs Market Analysis
- 5.5.1 China Duchenne Muscular Dystrophy Drugs Production
- 5.5.2 China Duchenne Muscular Dystrophy Drugs Revenue
- 5.5.3 Key Manufacturers in China
- 5.5.4 China Duchenne Muscular Dystrophy Drugs Import and Export
- 5.6 Japan Duchenne Muscular Dystrophy Drugs Market Analysis
- 5.6.1 Japan Duchenne Muscular Dystrophy Drugs Production
- 5.6.2 Japan Duchenne Muscular Dystrophy Drugs Revenue
- 5.6.3 Key Manufacturers in Japan
- 5.6.4 Japan Duchenne Muscular Dystrophy Drugs Import and Export
- 5.7 Southeast Asia Duchenne Muscular Dystrophy Drugs Market Analysis
- 5.7.1 Southeast Asia Duchenne Muscular Dystrophy Drugs Production
- 5.7.2 Southeast Asia Duchenne Muscular Dystrophy Drugs Revenue
- 5.7.3 Key Manufacturers in Southeast Asia
- 5.7.4 Southeast Asia Duchenne Muscular Dystrophy Drugs Import and Export
- 5.8 India Duchenne Muscular Dystrophy Drugs Market Analysis
- 5.8.1 India Duchenne Muscular Dystrophy Drugs Production
- 5.8.2 India Duchenne Muscular Dystrophy Drugs Revenue
- 5.8.3 Key Manufacturers in India
- 5.8.4 India Duchenne Muscular Dystrophy Drugs Import and Export
6 Duchenne Muscular Dystrophy Drugs Segment Market Analysis (by Type)
- 6.1 Global Duchenne Muscular Dystrophy Drugs Production by Type
- 6.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Type
- 6.3 Duchenne Muscular Dystrophy Drugs Price by Type
7 Duchenne Muscular Dystrophy Drugs Segment Market Analysis (by Application)
- 7.1 Global Duchenne Muscular Dystrophy Drugs Consumption by Application
- 7.2 Global Duchenne Muscular Dystrophy Drugs Consumption Market Share by Application (2014-2019)
8 Duchenne Muscular Dystrophy Drugs Major Manufacturers Analysis
- 8.1 Akashi Therapeutics Inc
- 8.1.1 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 8.1.2 Akashi Therapeutics Inc Product Introduction, Application and Specification
- 8.1.3 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.1.4 Main Business and Markets Served
- 8.2 Antisense Therapeutics Ltd
- 8.2.1 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 8.2.2 Antisense Therapeutics Ltd Product Introduction, Application and Specification
- 8.2.3 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.2.4 Main Business and Markets Served
- 8.3 Beech Tree Labs Inc
- 8.3.1 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 8.3.2 Beech Tree Labs Inc Product Introduction, Application and Specification
- 8.3.3 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.3.4 Main Business and Markets Served
- 8.4 Biogen Inc
- 8.4.1 Biogen Inc Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 8.4.2 Biogen Inc Product Introduction, Application and Specification
- 8.4.3 Biogen Inc Duchenne Muscular Dystrophy Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.4.4 Main Business and Markets Served
- 8.5 Bioleaders Corp
- 8.5.1 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 8.5.2 Bioleaders Corp Product Introduction, Application and Specification
- 8.5.3 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.5.4 Main Business and Markets Served
- 8.6 BioMarin Pharmaceutical Inc
- 8.6.1 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 8.6.2 BioMarin Pharmaceutical Inc Product Introduction, Application and Specification
- 8.6.3 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.6.4 Main Business and Markets Served
- 8.7 Biophytis SAS
- 8.7.1 Biophytis SAS Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 8.7.2 Biophytis SAS Product Introduction, Application and Specification
- 8.7.3 Biophytis SAS Duchenne Muscular Dystrophy Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.7.4 Main Business and Markets Served
- 8.8 Capricor Therapeutics Inc
- 8.8.1 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 8.8.2 Capricor Therapeutics Inc Product Introduction, Application and Specification
- 8.8.3 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.8.4 Main Business and Markets Served
- 8.9 Catabasis Pharmaceuticals Inc
- 8.9.1 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 8.9.2 Catabasis Pharmaceuticals Inc Product Introduction, Application and Specification
- 8.9.3 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.9.4 Main Business and Markets Served
- 8.10 CRISPR Therapeutics
- 8.10.1 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Production Sites and Area Served
- 8.10.2 CRISPR Therapeutics Product Introduction, Application and Specification
- 8.10.3 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.10.4 Main Business and Markets Served
- 8.11 Cumberland Pharmaceuticals Inc
- 8.12 Daiichi Sankyo Co Ltd
- 8.13 Debiopharm International SA
- 8.14 Editas Medicine Inc
- 8.15 Eloxx Pharmaceuticals Inc
- 8.16 F. Hoffmann-La Roche Ltd
- 8.17 FibroGen Inc
- 8.18 Fulcrum Therapeutics Inc
- 8.19 Galapagos NV
- 8.20 Genethon SA
- 8.21 GTx Inc
- 8.22 Santhera Pharmaceuticals Holding AG
- 8.23 Sarepta Therapeutics Inc
- 8.24 SOM Biotech SL
- 8.25 Strykagen Corp
- 8.26 Summit Therapeutics Plc
- 8.27 Taiho Pharmaceutical Co Ltd
- 8.28 Teijin Pharma Ltd
- 8.29 WAVE Life Sciences Ltd
9 Development Trend of Analysis of Duchenne Muscular Dystrophy Drugs Market
- 9.1 Global Duchenne Muscular Dystrophy Drugs Market Trend Analysis
- 9.1.1 Global Duchenne Muscular Dystrophy Drugs Market Size (Volume and Value) Forecast 2019-2025
- 9.2 Duchenne Muscular Dystrophy Drugs Regional Market Trend
- 9.2.1 North America Duchenne Muscular Dystrophy Drugs Forecast 2019-2025
- 9.2.2 Europe Duchenne Muscular Dystrophy Drugs Forecast 2019-2025
- 9.2.3 China Duchenne Muscular Dystrophy Drugs Forecast 2019-2025
- 9.2.4 Japan Duchenne Muscular Dystrophy Drugs Forecast 2019-2025
- 9.2.5 Southeast Asia Duchenne Muscular Dystrophy Drugs Forecast 2019-2025
- 9.2.6 India Duchenne Muscular Dystrophy Drugs Forecast 2019-2025
- 9.3 Duchenne Muscular Dystrophy Drugs Market Trend (Product Type)
- 9.4 Duchenne Muscular Dystrophy Drugs Market Trend (Application)
- 10.1 Marketing Channel
- 10.1.1 Direct Marketing
- 10.1.2 Indirect Marketing
- 10.3 Duchenne Muscular Dystrophy Drugs Customers
11 Market Dynamics
- 11.1 Market Trends
- 11.2 Opportunities
- 11.3 Market Drivers
- 11.4 Challenges
- 11.5 Influence Factors
12 Conclusion
13 Appendix
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Summary:
Get latest Market Research Reports on Duchenne Muscular Dystrophy Drugs. Industry analysis & Market Report on Duchenne Muscular Dystrophy Drugs is a syndicated market report, published as Global Duchenne Muscular Dystrophy Drugs Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Duchenne Muscular Dystrophy Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
